PRKDC and neoplasm: We demonstrate that AZD7648 is both an efficacious combination partner with the standard-of-care therapies IR and doxorubicin, as well as report robust anti-tumour activity of DNA-PK inhibition in combination with the PARP inhibitor, olaparib, in preclinical cancer models.